Boston Scientific Expects Taxus Inventory, Sales To Reach Pre-Recall Levels
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's Taxus drug-eluting stent inventory will climb 13% to 166,000 in October from 147,000 in September as the firm works to rebuild stock in the wake of a summer recall